Developing a new treatment for opioid use disorder using cebranopadol.
Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)
This study is testing a new medication called cebranopadol to see if it can help people with opioid use disorder by managing withdrawal symptoms while reducing the chances of abuse and dependence, giving participants a potential new option for their recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Park Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Morristown, United States) |
| Project ID | NIH-10897694 on NIH RePORTER |
What this research studies
This research focuses on cebranopadol, a novel medication designed to treat opioid use disorder (OUD) by acting on two types of opioid receptors in the brain. Unlike current treatments, cebranopadol aims to reduce the risks of abuse and physical dependence while effectively managing withdrawal symptoms. The approach involves both preclinical and clinical testing to evaluate its safety and efficacy. Patients participating in this research may receive a new therapeutic option that could improve their recovery from opioid addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking treatment alternatives.
Not a fit: Patients who are not struggling with opioid use disorder or those who have contraindications to cebranopadol may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for individuals struggling with opioid use disorder.
How similar studies have performed: While the approach of using a dual MOP/NOP agonist is innovative, similar research has shown promise in addressing opioid addiction, suggesting potential for success.
Where this research is happening
Morristown, United States
- Park Therapeutics, INC. — Morristown, United States (Active)
Researchers
- Principal investigator: Grieco, Joseph — Park Therapeutics, INC.
- Study coordinator: Grieco, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.